US FDA’s Bioresearch Monitoring Program Should Evaluate Hiring And Retention Strategies, GAO Says

BIMO inspections and investigators have declined since 2017, and investigators express frustration to the Government Accountability Office that their inspection classification recommendations are downgraded by the Center for Drug Evaluation and Research.